Milestone Pharmaceuticals (MIST) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 May, 2026Executive summary
The annual meeting is scheduled for June 10, 2026, to be held virtually, allowing shareholders to vote and participate online.
Shareholders will vote on director elections, auditor appointment, an equity plan amendment, and a say-on-pay proposal.
Proxy materials, including the annual report, are available online, with options for electronic or paper delivery.
Voting can be done online, by phone, mail, or during the virtual meeting, with detailed instructions provided.
Voting matters and shareholder proposals
Election of eight directors to serve until the 2027 annual meeting.
Ratification of PricewaterhouseCoopers LLP as auditor until the 2027 annual meeting and authorization for the board to set remuneration.
Approval of an amendment to the 2019 Equity Incentive Plan to increase shares authorized for issuance by 6,800,000.
Non-binding advisory vote on executive compensation (say-on-pay).
Shareholder proposals and director nominations for the 2027 meeting must be submitted by specified deadlines.
Board of directors and corporate governance
Board consists of eight members, seven of whom are independent; the CEO is the only non-independent director.
Board committees include Audit, Compensation, and Nominating and Corporate Governance, all composed of independent directors.
The board chair is independent, and directors are elected annually with no classified board structure.
Directors had a 99% attendance rate for board meetings and 93% for committee meetings in the last year.
The company maintains a robust code of business conduct and ethics and prohibits pledging or margin purchases of its securities by insiders.
Latest events from Milestone Pharmaceuticals
- FDA review targets March 2025, with a mid-year launch and broad access planned.MIST
Investor update14 May 2026 - Etripamil offers rapid, self-administered PSVT relief, meeting key unmet needs for many patients.MIST
Study update14 May 2026 - Shelf registration enables up to $300M in offerings, including $100M at-the-market with Cantor Fitzgerald.MIST
Registration filing13 May 2026 - Strong CARDAMYST launch, 600 prescriptions, $0.2M revenue, and expanding coverage in Q1 2026.MIST
Q1 202613 May 2026 - Virtual meeting to vote on directors, auditors, equity plan increase, and executive pay.MIST
Proxy filing30 Apr 2026 - CARDAMYST launches as the first new PSVT therapy in decades, targeting rapid market adoption.MIST
Corporate presentation29 Apr 2026 - FDA decision on CARDAMYST pending; net loss narrows as launch and new trials approach.MIST
Q4 202423 Apr 2026 - CARDAMYST launches with strong clinical data, broad provider targeting, and robust financial runway.MIST
25th Annual Needham Virtual Healthcare Conference13 Apr 2026 - CARDAMYST launched with strong early demand and $200M in cash, supporting growth into 2027.MIST
Q4 202520 Mar 2026